Amgen’s biosimilar was approved in Europe under the Bekemv brand name last year and competes in the EU with the Samsung Bioepis rival sold as Epysqli. Samsung Bioepis has also filed for approval ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

Amgen provided 2025 guidance ... with new launches expected in 2025, including BEKEMV (biosimilar to SOLIRIS). Product sales rose 19% year-over-year, driven by 23% volume growth.

Amgen is also preparing to launch its Stelara biosimilar, called Wezlana, in the U.S. in the first quarter of 2025. The U.S. launch of its Soliris biosimilar, named Bekemv, is expected to follow ...

Q4 2024 Management View Amgen highlighted its robust performance in 2024, achieving 14 products annualizing over $1 billion in sales. CEO Robert Bradway emphasized the company's resilience in ...